- Crescent Biopharma traded up 4.2% to $17.72 amidst lower-than-average volume, holding a market capitalization of $670.56 million and a consensus price target of $30.25.
- Wall Street analysts currently assign the company an average rating of Moderate Buy, while recent financial reports recorded a quarterly loss of $0.74 per share.
- Company executives sold a total of 68,156 shares valued at $1,226,126 over a three-month period to cover tax obligations, while institutional investors own 75.19% of the stock.
